-
Why Merck's Q1 Update Disappointed Investors Despite Beating Wall Street Estimates
Post on 4/29/20
-
Merck Reports First-Quarter Results, Lowers Guidance
Post on 4/29/20
-
Better Buy: Inovio Pharmaceuticals vs. GlaxoSmithKline
Post on 4/29/20
-
Rite Aid Loosens Its Criteria for Free COVID-19 Testing
Post on 4/29/20
-
Windtree Therapeutics Announces Reverse Stock Split
Post on 4/28/20
-
Merck Announces First-Quarter 2020 Financial Results
Post on 4/28/20
-
Pfizer Reports First-Quarter 2020 Results
Post on 4/28/20
-
Inovio Pharmaceuticals, Mesoblast, and Moderna: Are These Red-Hot Biotech Stocks Still a Buy?
Post on 4/27/20
-
Ambu Names Klaas-Pieter Jimmink Marketing Communications Director
Post on 4/27/20
-
States Where Social Distancing Is Most Difficult – WalletHub Study
Post on 4/27/20
-
70% of Investors Believe a COVID-19 Recession Will Be Worse Than 2008 -- But Here's the Silver Lining
Post on 4/27/20
-
Here’s Why Inovio Pharmaceuticals Is Soaring (Again) Today
Post on 4/27/20
-
Cyclacel Closes $20M Public Offering
Post on 4/26/20
-
Caladrius Biosciences Announces $5M Registered Direct Offering
Post on 4/26/20
-
Johnson & Johnson Taps Emergent BioSolutions to Help Manufacture Its COVID-19 Vaccine
Post on 4/24/20
-
Pfizer Declares $0.38 Dividend
Post on 4/24/20
-
Pfizer Targets Summer For COVID-19 Vaccine Human Trials; Potential Treatment Also In The Works
Post on 4/24/20
-
Better Buy: Amgen vs. Johnson & Johnson
Post on 4/24/20
-
Here's Why Immunomedics Shares Are Skyrocketing Today
Post on 4/24/20
-
Celsion Receives $2.5 Million Funding
Post on 4/23/20
-
SwanBio Therapeutics Announces Series A Expansion
Post on 4/23/20
-
Johnson & Johnson: The Defensive Stock To Own Through COVID-19
Post on 4/23/20
-
Will Johnson & Johnson's Coronavirus Vaccine Dominate the Market?
Post on 4/23/20
-
Better Coronavirus Stock: Johnson & Johnson vs. Inovio Pharmaceuticals
Post on 4/23/20
-
BioNTech Gets Green Light to Start Coronavirus Vaccine Trials in Germany
Post on 4/23/20
Philadelphia
